As of 2025-10-15, the EV/EBITDA ratio of Trillium Therapeutics Inc (TRIL.TO) is -43.31. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TRIL.TO's latest enterprise value is 2,476.46 mil CAD. TRIL.TO's TTM EBITDA according to its financial statements is -57.19 mil CAD. Dividing these 2 quantities gives us the above TRIL.TO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.0x - 35.0x | 23.5x |
| Forward P/E multiples | 12.0x - 35.0x | 23.5x |
| Fair Price | (7.46) - (23.89) | (15.67) |
| Upside | -132.0% - -202.4% | -167.2% |
| Date | EV/EBITDA |